CorMedix appoints Joseph Todisco as CEO effective by May 16, 2022

CorMedix Inc.

Joseph Todisco appointed CEO; expected start on or before May 16, 2022; will also join Board.
Todisco previously EVP, Chief Commercial Officer at Amneal; 20+ years pharma experience.
Employment agreement: $600k base salary, 65% target bonus, 500k stock options, 207k RSUs.
Dr. Matt David to continue as Interim CEO/CFO until Todisco starts, then remain CFO.
Company reaffirms focus on DefenCath NDA resubmission and commercial launch preparation.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joseph Todisco

Chief Executive Officer

CRMD · CorMedix Inc.

Filed: March 21, 2022, 7:59 PM ET

appointed Joseph Todisco as the Chief Executive Officer, commencing on such date as mutually agreed by Mr. Todisco and the Board, but in no event later than May 16, 2022.

Appointed

Joseph Todisco

Director

CRMD · CorMedix Inc.

Effective: 2022-03-18
Filed: March 21, 2022, 7:59 PM ET

Mr. Todisco was appointed to serve as a member of the Board on March 18, 2022.

Role change

Matthew T. David

Chief Financial Officer

CRMD · CorMedix Inc.

Successor: Joseph Todisco
Filed: March 21, 2022, 7:59 PM ET

Dr. Matthew T. David will continue to serve as Interim Chief Executive Officer and Chief Financial Officer until Mr. Todisco commences employment, after which Dr. David will continue to serve as our Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Todisco was appointed as Chief Executive Officer at CorMedix Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Joseph Todisco as the Chief Executive Officer, commencing on such date as mutually agreed by Mr. Todisco and the Board, but in no event later than May 16, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Todisco was appointed as Director at CorMedix Inc..

Action: appointed
Role: Director

Exact text from the filing

Mr. Todisco was appointed to serve as a member of the Board on March 18, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.85

Matthew T. David changed role as Chief Financial Officer at CorMedix Inc..

Role: Chief Financial Officer

Exact text from the filing

Dr. Matthew T. David will continue to serve as Interim Chief Executive Officer and Chief Financial Officer until Mr. Todisco commences employment, after which Dr. David will continue to serve as our Chief Financial Officer.

View on SEC.gov

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-013742

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.